Contineum Therapeutics, Inc. (CTNM)
CTNMNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$10.56
+0.2600 (+2.52%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $414.65m
- P/E
- –
- EPS, last 4 quarters
- $-1.77
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.73 to $17.79
- Average volume
- 873.3k
- Previous close
- $10.30
Analysts
7 coveringBuy5 buy, 2 hold, 0 sell
Targets a year out average $22.14, +109.7% from here
Earnings
next estimate $-0.4900Next report
Dec 2025
+2.0%
Mar 2026
+29.1%
Jun 2026
+13.0%
Sep 2026
-8.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$17.11m | -$16.90m | -$17.43m | -$20.97m |
| Net income | -$15.16m | -$14.46m | -$15.15m | -$18.70m |
News
8 latest- BMY Reports Mixed Phase III Trial Results, Stock DownZacks · Oct 13, 2026
- All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to BuyZacks · Oct 12, 2026
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead RTTNews · Sep 18, 2026
- Contineum's Phase 2 MOONLIGHT-1 Trial Misses Primary Endpoint In MDD; Stock Down RTTNews · Sep 15, 2026
- Show Me The Money: Contineum Therapeutics' Turnaround From Lows To New Highs RTTNews · Sep 4, 2026
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.The Motley Fool · Aug 31, 2026
- Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great ChoiceZacks · Jul 9, 2026
- Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?Zacks · May 25, 2026
The company
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- contineum-tx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.